Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05282771 · ClinicalTrials.gov registry record · Early Phase 1
A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
A Early Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 402
- Enrollment target
NCT05282771 is a Early Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 402 participants.
The verdict
NCT05282771, a Early Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 402 participants
- Enrollment target
Study Summary
To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045% (Reference Listed Drug) in the treatment of moderate to severe plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%
- DRUG Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2021-04-16 |
| Est. Completion | 2022-02-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05282771
The ClinicalTrials.gov registry entry for NCT05282771 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05282771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05282771 about?
NCT05282771 is a clinical study titled "A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.". To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045% (Reference Listed Drug) in the treatment of moderate to severe plaque psor...
What is the current status of trial NCT05282771?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 402 participants. The study started on 2021-04-16. Estimated completion is 2022-02-10.
What interventions are being tested in trial NCT05282771?
The interventions under investigation include: Placebo (DRUG), Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% (DRUG), Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045% (DRUG).
Who is sponsoring clinical trial NCT05282771?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.